Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Peptic Ulcer

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 87 articles:
HTML format
Text format



Single Articles


    September 2017
  1. FRASER AG
    Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori.
    Aliment Pharmacol Ther. 2017;46:550-551.
    PubMed     Text format    


  2. JUNG YS, Kim EH, Park CH
    Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply.
    Aliment Pharmacol Ther. 2017;46:551-552.
    PubMed     Text format    


  3. KAGAWA T, Iwamuro M, Inaba T
    Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms-authors' reply.
    Aliment Pharmacol Ther. 2017;46:566.
    PubMed     Text format    


  4. BAN H, Sugimoto M, Otsuka T, Murata M, et al
    Letter: a potassium-competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection-induced artificial ulcers after treatment of gastric neoplasms.
    Aliment Pharmacol Ther. 2017;46:564-565.
    PubMed     Text format    


  5. KOUNTOURAS J, Polyzos SA, Katsinelos P, Doulberis M, et al
    Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease.
    Aliment Pharmacol Ther. 2017;46:637-638.
    PubMed     Text format    


    August 2017
  6. KWON Y, Jeon S, Nam S, Shin I, et al
    Helicobacter pylori infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection.
    Aliment Pharmacol Ther. 2017 Aug 11. doi: 10.1111/apt.14263.
    PubMed     Text format     Abstract available


  7. ZAGARI RM, Rabitti S, Greenwood DC, Eusebi LH, et al
    Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis.
    Aliment Pharmacol Ther. 2017 Aug 7. doi: 10.1111/apt.14248.
    PubMed     Text format     Abstract available


    May 2017
  8. GENTA RM, Turner KO, Sonnenberg A
    Demographic and socioeconomic influences on Helicobacter pylori gastritis and its pre-neoplastic lesions amongst US residents.
    Aliment Pharmacol Ther. 2017 May 25. doi: 10.1111/apt.14162.
    PubMed     Text format     Abstract available


  9. LAURSEN SB, Leontiadis GI, Stanley AJ, Hallas J, et al
    The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding.
    Aliment Pharmacol Ther. 2017 May 23. doi: 10.1111/apt.14153.
    PubMed     Text format     Abstract available


  10. YI S, Lee H, Jang SB, Byun HM, et al
    A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
    Aliment Pharmacol Ther. 2017 May 21. doi: 10.1111/apt.14148.
    PubMed     Text format     Abstract available


  11. JUNG YS, Kim EH, Park CH
    Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2017 May 12. doi: 10.1111/apt.14130.
    PubMed     Text format     Abstract available


  12. COYLE C, Crawford G, Wilkinson J, Thomas SJ, et al
    Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
    Aliment Pharmacol Ther. 2017 May 2. doi: 10.1111/apt.14064.
    PubMed     Text format     Abstract available


    April 2017
  13. SUGIMOTO M, Ban H, Hira D, Kamiya T, et al
    Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan.
    Aliment Pharmacol Ther. 2017;45:1009-1010.
    PubMed     Text format    


    March 2017
  14. MASTRACCI L, Fiocca R, Engstrom C, Attwood S, et al
    The dynamics of the oesophageal squamous epithelium 'normalisation' process in patients with gastro-oesophageal reflux disease treated with long-term acid suppression or anti-reflux surgery.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14038.
    PubMed     Text format     Abstract available


  15. VAKIL N, Vieth M, Wernersson B, Wissmar J, et al
    Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14028.
    PubMed     Text format     Abstract available


  16. TALEBI BEZMIN ABADI A
    Letter: more studies are needed to elucidate any association between Helicobacter pylori infection and Barrett's metaplasia.
    Aliment Pharmacol Ther. 2017;45:764-765.
    PubMed     Text format    


    February 2017
  17. SHAW J, Bajaj JS
    Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients?
    Aliment Pharmacol Ther. 2017;45:476-477.
    PubMed     Text format    


  18. CHEN PY, Wu MS, Liou JM
    Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:573.
    PubMed     Text format    


  19. ZAMANI M, Shokri-Shirvani J, Zamani V
    Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2017;45:572-573.
    PubMed     Text format    


  20. AHN JS, Sinn DH, Son HJ, Gwak GY, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply.
    Aliment Pharmacol Ther. 2017;45:577-578.
    PubMed     Text format    


  21. KOUNTOURAS J, Polyzos SA, Kapetanakis N, Katsinelos P, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia.
    Aliment Pharmacol Ther. 2017;45:576-577.
    PubMed     Text format    


    January 2017
  22. SCHIAVON LL, Silva TE, Fischer J, Narciso-Schiavon JL, et al
    Letter: proton pump inhibitors and prognosis of cirrhosis - searching for the balance point.
    Aliment Pharmacol Ther. 2017;45:378-379.
    PubMed     Text format    


    November 2016
  23. MIWA H, Uedo N, Watari J, Mori Y, et al
    Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13876.
    PubMed     Text format     Abstract available


  24. SONNENBERG A, Turner KO, Spechler SJ, Genta RM, et al
    The influence of Helicobacter pylori on the ethnic distribution of Barrett's metaplasia.
    Aliment Pharmacol Ther. 2016 Nov 9. doi: 10.1111/apt.13854.
    PubMed     Text format     Abstract available


    October 2016
  25. COLE HL, Pennycook S, Hayes PC
    The impact of proton pump inhibitor therapy on patients with liver disease.
    Aliment Pharmacol Ther. 2016 Oct 23. doi: 10.1111/apt.13827.
    PubMed     Text format     Abstract available


  26. SAVARINO E, Girardin G, Della Coletta M, Ottonello A, et al
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;44:912-3.
    PubMed     Text format    


  27. MOLINA-INFANTE J, Katzka DA, Spechler SJ
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016;44:911-2.
    PubMed     Text format    


    September 2016
  28. MARTIN FC, Chenevix-Trench G, Yeomans ND
    Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Sep 15. doi: 10.1111/apt.13800.
    PubMed     Text format     Abstract available


  29. POINTER SD, Rickstrew J, Slaughter JC, Vaezi MF, et al
    Dietary carbohydrate intake, insulin resistance and gastro-oesophageal reflux disease: a pilot study in European- and African-American obese women.
    Aliment Pharmacol Ther. 2016 Sep 1. doi: 10.1111/apt.13784.
    PubMed     Text format     Abstract available


    August 2016
  30. PATEL A, Wang D, Sainani N, Sayuk GS, et al
    Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016 Aug 24. doi: 10.1111/apt.13777.
    PubMed     Text format     Abstract available


  31. MALMI H, Kautiainen H, Virta LJ, Farkkila MA, et al
    Letter: risk factor and mortality of peptic ulcer disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:425.
    PubMed     Text format    


  32. ZHANG XY, Mo HY, Huang Y
    Letter: risk factor and mortality of peptic ulcer disease.
    Aliment Pharmacol Ther. 2016;44:424-5.
    PubMed     Text format    


    July 2016
  33. KAGAWA T, Iwamuro M, Ishikawa S, Ishida M, et al
    Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
    Aliment Pharmacol Ther. 2016 Jul 28. doi: 10.1111/apt.13747.
    PubMed     Text format     Abstract available


  34. SAVARINO EV, Tolone S, Bartolo O, de Cassan C, et al
    The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon.
    Aliment Pharmacol Ther. 2016 Jul 4. doi: 10.1111/apt.13718.
    PubMed     Text format     Abstract available


  35. BYTZER P, Reimer C
    Letter: add-on alginate therapy for reflux patients with inadequate response to a once daily proton pump inhibitor - more questions than answers. Authors' reply.
    Aliment Pharmacol Ther. 2016;44:208.
    PubMed     Text format    


  36. CHEN PZ, Wang CC
    Letter: add-on alginate therapy for reflux patients with inadequate response to a once daily proton pump inhibitor - more questions than answers.
    Aliment Pharmacol Ther. 2016;44:207.
    PubMed     Text format    


    June 2016
  37. CHEN PY, Wu MS, Chen CY, Bair MJ, et al
    Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2016 Jun 30. doi: 10.1111/apt.13712.
    PubMed     Text format     Abstract available


  38. THUNG I, Crowe SE, Valasek MA
    Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Authors' reply.
    Aliment Pharmacol Ther. 2016;43:1249-50.
    PubMed     Text format    


  39. SHOKRI-SHIRVANI J, Zamani V, Zamani M
    Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions.
    Aliment Pharmacol Ther. 2016;43:1249.
    PubMed     Text format    


  40. MOLINA-INFANTE J, Lucendo AJ, Gisbert JP
    Letter: Helicobacter pylori infection and eosinophilic oesophagitis - causal or casual inverse association?
    Aliment Pharmacol Ther. 2016;43:1244.
    PubMed     Text format    


    May 2016
  41. MALMI H, Kautiainen H, Virta LJ, Farkkila MA, et al
    Increased short- and long-term mortality in 8146 hospitalised peptic ulcer patients.
    Aliment Pharmacol Ther. 2016 May 30. doi: 10.1111/apt.13682.
    PubMed     Text format     Abstract available


  42. HAASTRUP PF, Paulsen MS, Christensen RD, Sondergaard J, et al
    Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
    Aliment Pharmacol Ther. 2016 May 3. doi: 10.1111/apt.13649.
    PubMed     Text format     Abstract available


  43. WALKER AW, Flint HJ
    Editorial: further evidence that proton pump inhibitors may impact on the gut microbiota.
    Aliment Pharmacol Ther. 2016;43:1104-5.
    PubMed     Text format    


  44. REIMER C, Bytzer P
    Editorial: alginates for inadequate response to a proton pump inhibitor in gastro-oesophageal reflux disease - authors' reply.
    Aliment Pharmacol Ther. 2016;43:1104.
    PubMed     Text format    


  45. VAKIL N
    Editorial: alginates for inadequate response to a proton pump inhibitor in gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016;43:1103.
    PubMed     Text format    


    April 2016
  46. HESS MW, de Baaij JH, Broekman M, Bisseling TM, et al
    Inulin significantly improves serum magnesium levels in proton pump inhibitor-induced hypomagnesaemia.
    Aliment Pharmacol Ther. 2016 Apr 18. doi: 10.1111/apt.13619.
    PubMed     Text format     Abstract available


  47. KHAN F, Maradey-Romero C, Ganocy S, Frazier R, et al
    Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013.
    Aliment Pharmacol Ther. 2016 Apr 6. doi: 10.1111/apt.13611.
    PubMed     Text format     Abstract available


  48. LIOU JM, Chen MJ, Wu MS
    Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for Helicobacter pylori treatment? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:845-6.
    PubMed     Text format    


  49. LOSURDO G, Iannone A, Giorgio F, Principi M, et al
    Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for Helicobacter pylori treatment?
    Aliment Pharmacol Ther. 2016;43:844-5.
    PubMed     Text format    


    March 2016
  50. CAMUS M, Jensen DM, Kovacs TO, Jensen ME, et al
    Independent risk factors of 30-day outcomes in 1264 patients with peptic ulcer bleeding in the USA: large ulcers do worse.
    Aliment Pharmacol Ther. 2016 Mar 22. doi: 10.1111/apt.13591.
    PubMed     Text format     Abstract available


  51. KAGAMI T, Sahara S, Ichikawa H, Uotani T, et al
    Potent acid inhibition by vonoprazan in comparison with esomeprazole with reference to CYP2C19 genotype.
    Aliment Pharmacol Ther. 2016 Mar 18. doi: 10.1111/apt.13588.
    PubMed     Text format     Abstract available


  52. VERHAEGH BP, de Vries F, Masclee AA, Keshavarzian A, et al
    High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Mar 9. doi: 10.1111/apt.13583.
    PubMed     Text format     Abstract available


  53. PHILPOTT H, Nandurkar S, Royce SG, Thien F, et al
    A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis.
    Aliment Pharmacol Ther. 2016 Mar 4. doi: 10.1111/apt.13576.
    PubMed     Text format     Abstract available


  54. KUIPERS EJ
    Editorial: proton pump inhibitors, Helicobacter pylori and gastric cancer - the need for long-term follow-up.
    Aliment Pharmacol Ther. 2016;43:647-8.
    PubMed     Text format    


  55. EZEKWUDO D, Tobi M
    Letter: long-term use of proton pump inhibitors and risk of neuroendocrine tumours.
    Aliment Pharmacol Ther. 2016;43:749.
    PubMed     Text format    


  56. DEN HOLLANDER WJ, Sonnenschein-van der Voort AM, Holster IL, de Jongste JC, et al
    Helicobacter pylori in children with asthmatic conditions at school age, and their mothers.
    Aliment Pharmacol Ther. 2016 Mar 1. doi: 10.1111/apt.13572.
    PubMed     Text format     Abstract available


    February 2016
  57. CLOONEY AG, Bernstein CN, Leslie WD, Vagianos K, et al
    A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Feb 29. doi: 10.1111/apt.13568.
    PubMed     Text format     Abstract available


  58. VON ARNIM U, Wex T, Link A, Messerschmidt M, et al
    Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis.
    Aliment Pharmacol Ther. 2016 Feb 22. doi: 10.1111/apt.13560.
    PubMed     Text format     Abstract available


  59. REIMER C, Lodrup AB, Smith G, Wilkinson J, et al
    Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
    Aliment Pharmacol Ther. 2016 Feb 22. doi: 10.1111/apt.13567.
    PubMed     Text format     Abstract available


  60. LEOW AH, Lim YY, Liew WC, Goh KL, et al
    Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population - a 20-year experience over three time periods.
    Aliment Pharmacol Ther. 2016 Feb 5. doi: 10.1111/apt.13550.
    PubMed     Text format     Abstract available


    January 2016
  61. INABA T, Iwamuro M, Toyokawa T, Okada H, et al
    Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy.
    Aliment Pharmacol Ther. 2016;43:179-80.
    PubMed     Text format    


    December 2015
  62. THUNG I, Aramin H, Vavinskaya V, Gupta S, et al
    Review article: the global emergence of Helicobacter pylori antibiotic resistance.
    Aliment Pharmacol Ther. 2015 Dec 23. doi: 10.1111/apt.13497.
    PubMed     Text format     Abstract available


  63. LIOU JM, Chen CC, Lee YC, Chang CY, et al
    Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2015 Dec 15. doi: 10.1111/apt.13495.
    PubMed     Text format     Abstract available


  64. GOMEZ-TORRIJOS E, Garcia-Rodriguez R, Castro-Jimenez A, Rodriguez-Sanchez J, et al
    The Efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia.
    Aliment Pharmacol Ther. 2015 Dec 10. doi: 10.1111/apt.13496.
    PubMed     Text format     Abstract available


    November 2015
  65. ROBERTS SE, Morrison-Rees S, Samuel DG, Thorne K, et al
    Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe.
    Aliment Pharmacol Ther. 2015 Nov 23. doi: 10.1111/apt.13474.
    PubMed     Text format     Abstract available


  66. ASHIDA K, Sakurai Y, Hori T, Kudou K, et al
    Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Aliment Pharmacol Ther. 2015 Nov 11. doi: 10.1111/apt.13461.
    PubMed     Text format     Abstract available


  67. SCHNEIDER JL, Kolitsopoulos F, Corley DA
    Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors.
    Aliment Pharmacol Ther. 2015 Nov 6. doi: 10.1111/apt.13450.
    PubMed     Text format     Abstract available


    September 2015
  68. TURNER KO, Genta RM, Sonnenberg A
    Oesophageal signet ring cell carcinoma as complication of gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2015 Sep 8. doi: 10.1111/apt.13395.
    PubMed     Text format     Abstract available


  69. SHAH SL, Lacy BE, DiBaise JK, Vela MF, et al
    The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy.
    Aliment Pharmacol Ther. 2015 Sep 8. doi: 10.1111/apt.13394.
    PubMed     Text format     Abstract available


    August 2015
  70. DING Z, Zhao S, Gong S, Li Z, et al
    Prevalence and risk factors of Helicobacter pylori infection in asymptomatic Chinese children: a prospective, cross-sectional, population-based study.
    Aliment Pharmacol Ther. 2015 Aug 14. doi: 10.1111/apt.13364.
    PubMed     Text format     Abstract available


  71. MARCUS EA, Sachs G, Scott DR
    Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.
    Aliment Pharmacol Ther. 2015 Aug 4. doi: 10.1111/apt.13346.
    PubMed     Text format     Abstract available


  72. WALDUM HL, Hauso O, Fossmark R
    Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia.
    Aliment Pharmacol Ther. 2015;42:389.
    PubMed     Text format    


  73. MOAWAD FJ
    Editorial: proton pump inhibitor-responsive oesophageal eosinophilia - two different phenotypes? - Author's reply.
    Aliment Pharmacol Ther. 2015;42:487-8.
    PubMed     Text format    


  74. MOLINA-INFANTE J, Katzka DA
    Editorial: proton pump inhibitor-responsive oesophageal eosinophilia - two different phenotypes?
    Aliment Pharmacol Ther. 2015;42:485-7.
    PubMed     Text format    


    July 2015
  75. SUN J, Yang C, Zhao H, Zheng P, et al
    Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Aliment Pharmacol Ther. 2015 Jul 31. doi: 10.1111/apt.13334.
    PubMed     Text format     Abstract available


  76. ASHIDA K, Sakurai Y, Nishimura A, Kudou K, et al
    Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
    Aliment Pharmacol Ther. 2015 Jul 22. doi: 10.1111/apt.13331.
    PubMed     Text format     Abstract available


  77. SAKURAI Y, Mori Y, Okamoto H, Nishimura A, et al
    Randomised clinical trial: acid-inhibitory effect of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study.
    Aliment Pharmacol Ther. 2015 Jul 21. doi: 10.1111/apt.13325.
    PubMed     Text format     Abstract available


  78. LUNDELL L, Vieth M, Gibson F, Nagy P, et al
    Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
    Aliment Pharmacol Ther. 2015 Jul 16. doi: 10.1111/apt.13324.
    PubMed     Text format     Abstract available


  79. KAPPELLE WF, Bredenoord AJ, Conchillo JM, Ruurda JP, et al
    Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial.
    Aliment Pharmacol Ther. 2015 Jul 8. doi: 10.1111/apt.13306.
    PubMed     Text format     Abstract available


  80. ESTBORN L, Joelson S
    Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies.
    Aliment Pharmacol Ther. 2015 Jul 3. doi: 10.1111/apt.13304.
    PubMed     Text format     Abstract available


    June 2015
  81. TSENG CL, Chen YT, Huang CJ, Luo JC, et al
    Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study.
    Aliment Pharmacol Ther. 2015 Jun 22. doi: 10.1111/apt.13298.
    PubMed     Text format     Abstract available


  82. SUGIMOTO M, Sahara S, Ichikawa H, Kagami T, et al
    High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
    Aliment Pharmacol Ther. 2015 Jun 15. doi: 10.1111/apt.13280.
    PubMed     Text format     Abstract available


    May 2015
  83. TAHA AS, McCloskey C, Craigen T, Simpson A, et al
    Occult vs. overt upper gastrointestinal bleeding - inverse relationship and the use of mucosal damaging and protective drugs.
    Aliment Pharmacol Ther. 2015 May 24. doi: 10.1111/apt.13265.
    PubMed     Text format     Abstract available


  84. HARB AH, Chalhoub JM, Abou Mrad R, Sharara AI, et al
    Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2015 May 24. doi: 10.1111/apt.13259.
    PubMed     Text format     Abstract available


  85. MOAWAD FJ, Wells JM, Johnson RL, Reinhardt BJ, et al
    Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2015 May 24. doi: 10.1111/apt.13258.
    PubMed     Text format     Abstract available


    December 2014
  86. HOWDEN CW
    PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin.
    Aliment Pharmacol Ther. 2014;40.
    PubMed     Text format    


  87. IWAKIRI R, Fujimoto K
    PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin - authors' reply.
    Aliment Pharmacol Ther. 2014;40.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: